This study is a multi-center, open label, dose titration, exploratory study to evaluate efficacy and safety of CS-3150 in Japanese hypertensive patients with moderate renal impairment. Primary endpoint is change from baseline in sitting systolic and diastolic blood pressure.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
33
Unnamed facility
Osaka, Japan
Change from baseline in sitting systolic and diastolic blood pressure
Time frame: Baseline to end of Week 12
Change from baseline in UACR
Urine Albumin Creatinine Ratio (UACR)
Time frame: Baseline to end of Week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.